News

Unicycive Therapeutics Highlights Innovations at Kidney Week 2024

Unicycive Therapeutics Highlights Innovations at Kidney Week 2024

Unicycive Therapeutics Showcases Key Research at ASN Kidney Week

LOS ALTOS, Calif. – Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a pioneering biotechnology company focused on developing effective therapies for kidney diseases, has recently made a significant announcement. A poster presentation concerning their innovative treatment Oxylanthanum Carbonate (OLC) was selected for a Late-Breaker session at the American Society of Nephrology (ASN) Kidney Week 2024. Thus, the excitement surrounding OLC continues to build, especially as the company prepares to share more groundbreaking insights into their additional research on both OLC and another candidate, UNI-494.

Details About the Late-Breaking Science Poster

Late Breaking Science Poster:

Title: Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia

Lead Author: Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer & Senior Vice President at U.S. Renal Care.

Session Title: Late-Breaking Science Posters [LB-PO]

Poster Board: #TH-PO1188

Date/Time: Thursday, October 24, 2024, from 10:00 a.m. – 12:00 p.m. PT

Exciting Additional Presentations

Unicycive will also be delivering three additional poster presentations at Kidney Week, showcasing their comprehensive research efforts:

1. Title: Intravenous UNI-494 Slows Progression or Halts/Reverses Acute Kidney Injury

Lead Author: Satya Medicherla, Ph.D., Vice President of Preclinical Pharmacology at Unicycive.

Session Title: AKI: Mechanisms

Poster Board: #FR-PO155

Date/Time: Friday, October 25, 2024, from 10:00 a.m. – 12:00 p.m. PT

Other Notable Poster Presentations

2. Title: Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rat

Lead Author: Satya Medicherla, Ph.D.

Session Title: CKD-MBD: Basic and Translational

Poster Board: #SA-PO243

Date/Time: Saturday, October 26, 2024, from 10:00 a.m. – 12:00 p.m. PT

Final Presentation

3. Title: UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics

Lead Author: Guru Reddy, PH.D., Vice President of Preclinical R&D at Unicycive.

Session Title: AKI: Clinical, Outcomes, and Trials - Management

Poster Board: #SA-PO036

Date/Time: Saturday, October 26, 2024, from 10:00 a.m. – 12:00 p.m. PT

Understanding Oxylanthanum Carbonate (OLC)

Oxylanthanum carbonate is emerging as a next-generation lanthanum-based phosphate-binding agent, specifically designed for treating hyperphosphatemia in patients suffering from chronic kidney disease (CKD). With over forty patents issued globally, OLC demonstrates potential advantages over existing treatments as it promises to reduce the pill burden for patients, thus likely improving adherence. The results from a survey completed in 2022 indicated that nephrologists are particularly focused on finding solutions that alleviate the pill burden associated with traditional phosphate binders.

A Promising Market Opportunity

The market for addressing hyperphosphatemia is colossal, projected to exceed $2.5 billion with a significant portion attributed to the U.S. This thriving sector continues to emphasize the necessity for effective treatments, as a staggering 75% of dialysis patients in the U.S. do not reach their recommended phosphorus levels, despite the options available.

Regulatory Pathway and Clinical Trials

Unicycive is actively seeking FDA approval for OLC via the 505(b)(2) regulatory pathway. The company has conducted two pivotal clinical studies on healthy volunteers, including a safety and tolerability study, establishing the groundwork for future progress. A key clinical trial also examined the efficacy of OLC in CKD patients on hemodialysis, resulting in favorable outcomes.

About UNI-494

UNI-494 represents an advancement in the treatment of acute kidney injury (AKI). As a novel nicotinamide ester derivative, it uniquely activates mitochondrial potassium channels, spotlighting the importance of mitochondrial function in kidney health. This product is currently undergoing a Phase 1 dose-ranging safety study, with results anticipated soon, further underscoring Unicycive’s commitment to combatting kidney illnesses.

Conclusion

Unicycive Therapeutics continues to make strides in the field of kidney disease therapy, committed to furthering innovation for patients suffering from these conditions. Their upcoming presentations at ASN Kidney Week 2024 signify not only the advancements of OLC and UNI-494 but also the company’s dedication to addressing the serious challenges within nephrology.

Frequently Asked Questions

What is Oxylanthanum Carbonate (OLC)?

OLC is an innovative lanthanum-based phosphate binding agent aimed at treating hyperphosphatemia in chronic kidney disease patients.

When will Unicycive present their research?

Unicycive will present at ASN Kidney Week from October 24-27, 2024.

Who are the lead authors for the presentations?

Lead authors include several prominent professionals, such as Geoffrey A. Block, MD, and Satya Medicherla, Ph.D.

What is the market potential for treating hyperphosphatemia?

The global market for hyperphosphatemia treatments is projected to exceed $2.5 billion with significant unmet needs in patient adherence.

What is the significance of UNI-494?

UNI-494 is potentially a significant advancement in treating acute kidney injury through its unique mechanism of enhancing mitochondrial function.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Workers at CertainTeed Plant Unionize with Teamsters

Updated Category News Views 17

Unity at CertainTeed Sends Ripples through Industry Here's something that'll stir your coffee: 170 workers at CertainTeed's fiberglass facility in Chowchilla, California, just decided they won't take management's antics lying down. These folks voted to join Teamsters Local 431, aiming for some long-overdue respect and a contract that'll guarantee better wages and...

Continue Reading
Parloa's AI Agents Boost SAP Customer Experience

Updated Category News Views 145

AI Meets SAP in Customer Experience Revolution Alright, let's cut through the tech chatter. Parloa’s Agent Management Platform has hitched its wagon to SAP as a spiffy Solution Extension. This isn't just tech fluff—it’s a big step for scratching that CX itch companies have. By merging Parloa's AI magic with SAP's existing mojo, businesses get a toolset to enhance...

Continue Reading
Medline's Decade-Long WRAP Partnership: More Than Labels

Updated Category News Views 144

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

Continue Reading
SurgeONE's Avery Actions: Pioneering AI in Compliance

Updated Category News Views 116

Revolutionizing Compliance with Avery Actions A brand spanking new player has stepped onto the compliance stage, and it's swinging a pretty big AI bat. SurgeONE.ai unveiled Avery Actions, an industry-first agentic AI platform that's aiming to wrangle all your compliance, cybersecurity, and data governance operations under one interoperable umbrella. It's a bold move, and...

Continue Reading
111, Inc. Strategizes with Advisors Amid Proposal Talks

Updated Category News Views 105

Every time a company's board starts tossing around phrases like "strategic alternatives," you’ve got to pay closer attention. 111, Inc., holding the NASDAQ ticker YI, is one such entity at a crossroads. They've enlisted Houlihan Lokey China Limited as their independent financial advisor and Kirkland & Ellis as their U.S. legal counsel to sift through potential strategic...

Continue Reading
Huntington Bank Bolsters Westside Future Fund with $1M Boost

Updated Category News Views 95

Huntington's Commitment Goes Beyond Dollars In a world where corporations often toss out pretty phrases without the substance to back them up, Huntington Bank's $1 million shout-out to Atlanta's Westside Future Fund (WFF) speaks volumes. This ain't your run-of-the-mill PR move. It's a solid, tangible effort to help a community that's rich in history but screaming for...

Continue Reading
AVANT BIO Beef Up Team with Heavyweights Lio, Vanek

Updated Category News Views 117

AVANT BIO's Latest Power Play Alright, here's a big splash in the gene pool of life sciences—AVANT BIO just drafted two industry veterans, Peggy Lio and Philip Vanek, into their Operating Advisor Hall of Fame. And these folks aren't just window dressing. They're packing experience from some of the big hitters like GE Healthcare and Lonza, ready to roll up their sleeves...

Continue Reading
Pizza & Hope: Little Caesars Serves WV Communities

Updated Category News Views 32

Rolling Out Dough and Kindness in West Virginia In a world that's more uncertain than a penny stock, here comes a story that'll warm even the coldest heart: Little Caesars is sending their Love Kitchen into West Virginia, aiming to serve piping hot pizza to about 8,000 folks in need. Fueled by the efforts of local franchisee Vicki Dunn-Marshall and her team, they're...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 347

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading
Artprice Champions Creative Freedom with AI in 2026

Updated Category News Views 89

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

Continue Reading

Top 5 Most Recently Viewed Articles

Telitacicept Shows Promising Results for Myasthenia Gravis Treatment

Updated Category News Views 201

Exciting Developments in Myasthenia Gravis Treatment Recent reports have highlighted the positive impact of Telitacicept on patients suffering from generalized myasthenia gravis (gMG). During a 48-week open-label extension of a Phase 3 study, conducted in collaboration with RemeGen Co., Ltd, the efficacy and safety of this treatment were put to the test. The results...

Continue Reading
Lyell Immunopharma Secures Major Funding for Innovative Therapies

Updated Category News Views 287

Lyell Immunopharma's Strategic Funding Announcement Lyell Immunopharma, Inc. (NASDAQ: LYEL), a pioneering clinical-stage company, recently declared an exciting advancement in their funding strategy with a private placement of equity aimed at generating up to $100 million. This initiative signifies a robust step forward in their mission to develop next-generation CAR...

Continue Reading
AI Catalyzes Growth in Global Fresh Cranberries Market

Updated Category News Views 91

The fresh cranberries market was on the cusp of significant growth back in 2024. Analysts were buzzing with projections estimating an increase of USD 11.6 million from 2024 to 2028. This upswing was largely attributed to a surge in consumer awareness about the health benefits of fresh cranberries and the integration of innovative technologies like artificial intelligence...

Continue Reading
BON's Innovative Agreement for Hypoglycemic Product Expansion

Updated Category News Views 255

BON Natural Life Limited Launches Revolutionary Hypoglycemic Product Series With its recent announcement, Bon Natural Life Limited (Nasdaq: BON) is paving the way for innovative solutions in blood sugar management. This exciting initiative is in collaboration with Beijing Huahai Keyuan (Tech) Co., Ltd., a respected distributor in the functional ingredient sector. Over the...

Continue Reading
Get Ready for the Hill Country Mile Rod Run This Fall!

Updated Category News Views 90

Get Ready for the Hill Country Mile Rod Run This Fall As fall approaches, car enthusiasts everywhere are gearing up for an exhilarating event in Boerne, Texas. The Hill Country Mile Rod Run is set to bring together an impressive lineup of classic cars, trucks, and motorcycles, creating a vibrant gathering for automobile lovers of all backgrounds. This year’s event is...

Continue Reading